| Q40149086 | 11 Insulin receptors in normal and disease states |
| Q34612016 | A mutation in the B chain coding region is associated with impaired proinsulin conversion in a family with hyperproinsulinemia |
| Q34345376 | A superactive insulin: [B10-aspartic acid]insulin(human). |
| Q34558557 | Biochemical and clinical implications of proinsulin conversion intermediates |
| Q40173379 | Biologic and Clinical Importance of Proinsulin |
| Q40324427 | Biosynthesis of insulin and glucagon. |
| Q34521125 | Diabetes due to secretion of a structurally abnormal insulin (insulin Wakayama). Clinical and functional characteristics of [LeuA3] insulin |
| Q36262276 | Extrapancreatic insulin gene expression in the fetal rat |
| Q34605349 | Familial hyperproinsulinemia. Two cohorts secreting indistinguishable type II intermediates of proinsulin conversion |
| Q35600184 | Genetic epidemiology of type 1 diabetes |
| Q40178183 | Golgi/granule processing of peptide hormone and neuropeptide precursors: A minireview |
| Q39591958 | Human biochemical genetics of enzyme proteins in the new age of molecular genetics |
| Q34609676 | Human insulin B24 (Phe----Ser). Secretion and metabolic clearance of the abnormal insulin in man and in a dog model |
| Q37506718 | Identification of a mutant human insulin predicted to contain a serine-for-phenylalanine substitution |
| Q40325465 | Insulin biosynthesis and diabetes mellitus |
| Q38213044 | Insulin gene mutations and diabetes |
| Q48320964 | Insulin resistance by unprocessed insulin proreceptors point mutation at the cleavage site |
| Q37393881 | Molecular basis of hemophilia B: a defective enzyme due to an unprocessed propeptide is caused by a point mutation in the factor IX precursor |
| Q33866630 | Partial diversion of a mutant proinsulin (B10 aspartic acid) from the regulated to the constitutive secretory pathway in transfected AtT-20 cells |
| Q54049618 | Pathogenesis of non-insulin-dependent (type II) diabetes mellitus (NIDDM) - genetic predisposition and metabolic abnormalities. |
| Q70250804 | Pathogenetic mechanisms of hereditary diabetes mellitus |
| Q40919434 | Posttranslational cleavage of proinsulin is blocked by a point mutation in familial hyperproinsulinemia |
| Q39658694 | Precursors to regulatory peptides: their proteolytic processing |
| Q51596498 | Prevalence of beta allele of the insulin gene in type II diabetes mellitus. |
| Q41841558 | Proinsulin modified by analogues of arginine and lysine is degraded rapidly in pancreatic B-cells |
| Q42164707 | Proteolytic conversion of proinsulin into insulin. Identification of a Ca2+-dependent acidic endopeptidase in isolated insulin-secretory granules |
| Q68047453 | Scintigraphic distribution of 123 I labelled proinsulin, split conversion intermediates and insulin in rats |
| Q40076283 | Scope of DNA cloning and chemical methods in development of chemotherapeutic agents |
| Q40095489 | Secretory granules |
| Q37481771 | Sequence requirements for cleavage activation of influenza virus hemagglutinin expressed in mammalian cells |
| Q37618293 | Studies on mutant human insulin genes: identification and sequence analysis of a gene encoding [SerB24]insulin |
| Q36647478 | The Jeremiah Metzger Lecture. From POMC to functional diversity of neural peptides: the key importance of convertases. |
| Q40246528 | The definition and classification of diabetes mellitus |
| Q93557927 | The primary structure of ratfish insulin reveals an unusual mode of proinsulin processing |
| Q39731835 | The processing of peptide precursors. 'Proline-directed arginyl cleavage' and other monobasic processing mechanisms |
| Q37072233 | The regulated secretory pathway and human disease: insights from gene variants and single nucleotide polymorphisms |
| Q54498926 | Three mutant insulins in man |